Isaiah Fields Sells 2,000 Shares of Axon Enterprise (NASDAQ:AXON) Stock

Axon Enterprise, Inc (NASDAQ:AXON) insider Isaiah Fields sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $400.00, for a total transaction of $800,000.00. Following the sale, the insider directly owned 52,813 shares in the company, valued at $21,125,200. The trade was a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Isaiah Fields also recently made the following trade(s):

• On Friday, February 27th, Isaiah Fields sold 2,000 shares of Axon Enterprise stock. The stock was sold at an average price of $535.01, for a total transaction of $1,070,020.00.

Axon Enterprise Trading Up 1.6%

AXON opened at $391.32 on Thursday. Axon Enterprise, Inc has a fifty-two week low of $339.01 and a fifty-two week high of $885.91. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.27 and a quick ratio of 1.93. The firm has a market capitalization of $31.54 billion, a price-to-earnings ratio of 157.16, a PEG ratio of 7.01 and a beta of 1.44. The company’s 50 day moving average price is $410.07 and its two-hundred day moving average price is $496.12.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm had revenue of $807.35 million for the quarter, compared to analyst estimates of $778.91 million. During the same period in the previous year, the firm posted $1.47 EPS. The company’s revenue for the quarter was up 33.7% compared to the same quarter last year. As a group, research analysts predict that Axon Enterprise, Inc will post 1.82 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on AXON shares. TD Cowen reduced their price objective on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating on the stock in a research note on Wednesday, April 8th. William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 3rd. Craig Hallum reiterated a “buy” rating and set a $820.00 price objective on shares of Axon Enterprise in a research report on Wednesday, February 25th. Weiss Ratings upgraded shares of Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Finally, The Goldman Sachs Group set a $535.00 price objective on shares of Axon Enterprise in a research report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $712.75.

Institutional Investors Weigh In On Axon Enterprise

Several large investors have recently modified their holdings of the company. Baillie Gifford & Co. boosted its stake in Axon Enterprise by 1,198.7% during the fourth quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock worth $932,869,000 after acquiring an additional 1,516,099 shares in the last quarter. Edgewood Management LLC bought a new position in Axon Enterprise during the fourth quarter worth $846,516,000. Wellington Management Group LLP boosted its stake in Axon Enterprise by 326.9% during the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock worth $874,463,000 after acquiring an additional 1,179,038 shares in the last quarter. Norges Bank bought a new position in Axon Enterprise during the fourth quarter worth $515,764,000. Finally, Vanguard Group Inc. boosted its stake in Axon Enterprise by 4.2% during the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after acquiring an additional 376,904 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.